We’re proud to announce the internal publication of our newest white paper, exclusively available now for our Cannabis-Startups FAMILYMEMBER and readers of this blog.
This paper explores a timely and pressing question:
How can North American cannabis companies strategically enter the European market—starting with Germany’s groundbreaking Cannabis Act (CanG)?
Germany: The Entry Point for Europe’s Cannabis Economy
Following the historic legalization of adult-use cannabis in Germany under the CanG in April 2024, the European cannabis market is undergoing a significant shift. With over 72 tons of medical cannabis imported in 2024 and a projected EU market size of $6.2 billion by year’s end, the time to act is now.
From Cultivation Associations and pharmacy distribution to white-label strategies and medical exports, Germany offers a launchpad unlike any other in Europe.
What You’ll Learn
In this white paper, we cover:
-
The two-pillar structure of the Cannabis Act (CanG)
-
Strategic entry options for U.S. and Canadian companies under current EU regulations
-
High-growth verticals like home grow tech, GMP-certified post-harvest systems, and club partnerships
-
Legal structuring, import timelines, and compliance tips for success in Germany and beyond
Who Should Read This
This white paper is essential reading for:
-
U.S. and Canadian cultivators, processors, and medical brands
-
Cannabis tech providers and ancillary service companies
-
Investors exploring cross-border opportunities
-
Global operators with eyes on long-term scalability across Europe
Inner Circle Access Now—Global Media Coverage Coming Soon
We’re currently sharing this report with our inner circle of founders, investors, and policy experts. Broader media coverage will follow shortly, including features in select North American cannabis publications.
📰 Stay tuned for interviews and analysis across the U.S. and Canada in the coming weeks.
